SILVER SPRING, Md., April 1, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") today announced financial results for the fiscal year ended December 31, 2012. On a consolidated basis, net revenues for the fiscal year 2012 totaled $4.26 mln vs. 2011 of $863K, representing 490% growth year-over-year. The company had one-time, non-recurring expenses of $1.2 mln related to going public and the investments it made in building a foundation for future growth. The company spent much of 2012 building the cornerstones for a move toward profitability in 2013. This included acquiring BryceRx Laboratories, Inc., which not only grew the company's topline with prescription based revenue but also dramatically increased the company's gross profit.
Pharmagen's branded OTC product, Clotamin™, has demonstrated consistent momentum growing from being carried in several hundred stores to being carried nationally at over 7,000 locations at one of the leading pharmacy chains in the world. The company has made significant investments in Clotamin and expects continued growth of the product across other major national retailers and internationally.
From a brand prospective, the company went through a strategic realignment. Pharmagen is now moving toward being the leader in pragmatic solutions to the drug shortage crisis in the United States. With a multifaceted approach, the company is meeting the demands of the health provider market through dynamic, independent wholesale, compounding/admix, and innovative IT solutions. The company grew its Pharmagen Distribution pharmaceutical wholesale license base to 47 states and continues to rapidly grow Pharmagen Laboratories license base as well. The company made significant investment across the board from IT, accounting, equipment and personnel.
Pharmagen brought on a Chief Financial Officer from a major hospital system, Eric Clarke. Clarke brings over 17 years of extensive health care and financial expertise. Prior to joining Pharmagen, Clarke served as part of the leadership team at MedStar Health; a $4 billion diversified health system in the Washington D.C. region, which includes leading medical facilities such as Washington Hospital Center and Georgetown University Hospital. Additionally, Clarke formally served as the Managing Director in charge of the Washington D.C., Risk Management Practice for a national professional services firm, providing expert advice and service in forensic accounting, SEC reporting, and Sarbanes-Oxley Compliance.
With an eye on profitability, the company continues to keep operating expenses as low as possible and is actively exploring all opportunities that benefit shareholders. These endeavors include but are not limited to a strategic relocation to lower the company's tax burden, growing the company's institutional shareholder base by partnering with investment banks and a professional investment relations firm, attending financial conferences and staying at the forefront of health policy by engaging health regulators.
Leveraging our understanding of drug shortages, our long term goal is to become an FDA approved manufacturer of habitually short supply, sterile pharmaceuticals. Through an industry changing, cGMP + ® process, employing single-use, modular systems, we intend to be the gold standard of sterile production in the United States.
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.
Contact: 888-264-4597 or firstname.lastname@example.org
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned.
SOURCE Pharmagen, Inc.